Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL28135451 | 0.93 | ALDH1A1 (0.38) | ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL28841925 | 0.86 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL800 | 0.84 | ALDH1A1 (0.35) | ALDH1A1HTT | |
| SCHEMBL775457 | 0.80 | ALDH1A1 (0.40) | ALDH1A1TDP1HTT | |
| SCHEMBL2182293 | 0.77 | ALDH1A1 (0.45) | ALDH1A1TSHRHSD17B10TDP1LMNA | |
| Methylene Chloride SCHEMBL28135450 | 0.77 | HTT (0.31) | ALDH1A1HTT | |
| SCHEMBL25239528 | 0.76 | — | — | |
| Dimethyl Sulfoxide SCHEMBL9484693 | 0.76 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL7261664 | 0.76 | HSD17B10 (0.44) | ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL25286952 | 0.75 | HTT (0.30) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274833-A1 | PROCESS FOR MANUFACTURING AN AQUEOUS HYDROGEN PEROXIDE SOLUTION | SOLVAY SA (BE) | 2022-09-01 | — | — | US | claimed |
| EP-4028386-A1 | PROCESS FOR MANUFACTURING AN AQUEOUS HYDROGEN PEROXIDE SOLUTION | SOLVAY SA (BE) | 2022-07-20 | — | — | EP | claimed |
| CN-109317194-B | Catalyst for one-step synthesis of cyclic dipeptide and application thereof | 安阳师范学院 | 2021-08-24 | — | — | CN | claimed |
| WO-2021048368-A1 | PROCESS FOR MANUFACTURING AN AQUEOUS HYDROGEN PEROXIDE SOLUTION | SOLVAY SA (BE) | 2021-03-18 | — | — | WO | claimed |
| CN-106831636-A | A kind of preparation method of oxadiazole compound | 湖南华腾制药有限公司 | 2017-06-13 | — | — | CN | claimed |
| US-12606557-B2 | Substituted indoles with inhibitory activity | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-21 | — | — | US | disclosed |
| CN-116262675-B | Method for preparing malononitrile oxime ether compound | 沈阳中化农药化工研发有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-116496635-B | Synthesis method of vat blue | 宁夏保隆科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-11939327-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-26 | — | — | US | disclosed |
| EP-3693360-B1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20230278999-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-07 | — | — | US | disclosed |
| CN-116496635-A | Synthesis method of vat blue | 宁夏保隆科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-0371179-A1 | Novel analogs of peptidase substrates | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-06-06 | — | — | EP | disclosed |
| EP-0368719-A2 | Novel analogs of peptidase substrates | MERRELL PHARMACEUTICALS INC. (US) | 1990-05-16 | — | — | EP | disclosed |
| EP-0364344-A2 | Novel peptidase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1990-04-18 | — | — | EP | disclosed |
| EP-0362002-A1 | HIV protease inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| CN-1040582-A | New peptidase inhibitors | MERRELL DOW PHARMA (US) | 1990-03-21 | — | — | CN | disclosed |
| EP-0356595-A1 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
| EP-0275101-A2 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278999-A1 | HETEROCYCLIC COMPOUNDS | GRIN2C, GRIN1, GRIN2A | ALDH1A1 135/4885TSHR 571/4885HSD17B10 906/4885 |
| US-12606557-B2 | Substituted indoles with inhibitory activity | IDO1, BCL9, IDO2 | ALDH1A1 754/4885TSHR 500/4885HSD17B10 570/4885 |
| US-11939327-B2 | Heterocyclic compounds | GRIN2C, GRIN1, GRIN2A | ALDH1A1 147/4885TSHR 569/4885HSD17B10 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.